Inclusion Criteria for the Study

          1. Written informed consent and HIPAA authorization for release of personal health
             information explained to, understood by and signed by the subject or legally
             authorized representative.

          2. Age ≥ 18 years at the time of consent.

          3. Karnofsky score of >60%

          4. Histological or cytological evidence/confirmation of CD30+ peripheral T-cell lymphoma
             per the 2017 World Health Organization Classification of Haematopoietic and Lymphoid
             Tissues.

          5. CD30+ disease determined by biopsy after the subject's most recent anti-CD30 therapy
             prior to ATLCAR.CD30 (result can be pending at the time of cell procurement, but must
             be confirmed prior to treatment with the first infusion of ATLCAR.CD30 cells). NOTE:
             CD30+ disease requires documented CD30 expression by immunohistochemistry based on the
             institutional hematopathology standard.

          6. Subjects must have received at least two prior lines of therapy for their lymphoma. If
             transplant is given as a preplanned consolidation in first remission, it will not be
             counted as a second line of therapy.

          7. Subjects relapsed after autologous stem cell transplant are eligible for this study.

          8. Subjects relapsed after allogeneic stem cell transplantation are eligible provided the
             patient is ≥180 days from transplant, not on immunosuppresive therapy to treat/prevent
             graft-versus-host disease, and has no evidence of active graft-versus-host disease.

          9. Female subjects of childbearing potential must have a negative serum pregnancy test
             within 72 hours prior to cell procurement. Note: Females are considered of
             childbearing potential unless they are surgically sterile (have undergone a
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
             naturally postmenopausal for at least 12 consecutive months. Documentation of
             postmenopausal status must be provided.

         10. Female subjects of childbearing potential must be willing to abstain from heterosexual
             activity or to use 2 forms of effective methods of contraception from the time of
             informed consent until 6 months after study treatment discontinuation. The two
             contraception methods can be comprised of two barrier methods, or a barrier method
             plus a hormonal method or an intrauterine device that meets <1% failure rate for
             protection from pregnancy in the product label. Women of childbearing potential will
             also be instructed to tell their male partners to use a condom.

         11. Subject is willing and able to comply with study procedures based on the judgement of
             the investigator or protocol designee.

        Exclusion Criteria for the Study

          1. Subject is pregnant or lactating (Note: Breast milk cannot be stored for future use
             while the mother is being treated on study).

          2. Subject has a known additional malignancy that is active and/or progressive requiring
             treatment; exceptions include basal cell or squamous cell skin cancer, in situ
             cervical or bladder cancer, or other cancer for which the subject has been
             disease-free for at least five years.

          3. Subjects diagnosed with cutaneous T-cell lymphoma including mycosis fungoides, Sézary
             syndrome, or any other variant of cutaneous T-cell lymphoma.

          4. Current use of systemic corticosteroids at doses ≥10 mg prednisone daily or its
             equivalent; those receiving <10 mg daily may be enrolled at discretion of
             investigator. Inhaled steroids are allowed.

          5. Active infection with HIV, HTLV, HCV (tests can be pending at the time of cell
             procurement; only those samples confirming lack of active infection will be used to
             generate transduced cells). Note: To meet eligibility subjects are required to be
             negative for HIV antibody, negative for HTLV1 and 2 antibody or PCR negative for HTLV1
             and 2, negative for HCV antibody or HCV viral load.

          6. Subjects who are positive for hepatitis B surface antigen (can be pending at the time
             of cell procurement; only those samples confirming lack of active infection will be
             used to generate transduced cells) are excluded. Subjects who are hepatitis B surface
             antigen negative but hepatitis B core antibody positive must have their hepatitis B
             viral load checked. These subjects will be excluded if their viral load is positive at
             baseline. Subjects who are core antibody positive and viral load negative at baseline
             will be considered eligible.

        Eligibility Criteria Prior to Cell Procurement

          1. Informed consent to undergo cell procurement understood by and signed by the subject
             or legally authorized representative; subject and/or legally authorized representative
             given a copy of informed consent form for cell procurement.

          2. Subject has life expectancy ≥ 6 weeks.

          3. Subject has evidence of adequate organ function as defined by:

               -  Hemoglobin ≥8.0 g/dL (transfusion independent for 2 weeks prior to procurement)

               -  Total bilirubin ≤ 2 × ULN, unless attributed to Gilbert's Syndrome

               -  AST ≤ 3 × ULN

               -  ALT < 3 x ULN

               -  Creatinine ≤ 2 × ULN

               -  Pulse oximetry of >90% on room air

          4. Imaging results from within 90 days prior to procurement to assess presence of active
             disease.

          5. Negative serum pregnancy test within 72 hours prior to procurement or documentation
             that the subject is post-menopausal. Post-menopausal status must be confirmed with
             documentation of absence of menses for >1 year, or documentation of surgical menopause
             (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)
             or they are naturally postmenopausal for at least 12 consecutive months.

        Eligibility Criteria Prior to Lymphodepletion #1

          1. Written informed consent explained to, understood by and signed by the subject or
             legally authorized representative; subject and/or legally authorized representative
             given a copy of informed consent form.

          2. Imaging results from within 10 days prior to lymphodepletion. Imaging must occur at
             least 3 weeks after most recent therapy (used as baseline measure for documentation of
             progression before the lymphodepletion) to document measurable or assessable disease.

          3. Subject must demonstrate adequate organ function prior to lymphodepletion as defined
             below. All tests must be obtained within 72 hours prior to lymphodepletion:

               -  Absolute neutrophil count ≥ 1.0 × 10^9/L

               -  Platelet count ≥ 50 × 10^9/L

               -  Total bilirubin < 2 x ULN unless attributed to Gilbert's syndrome

               -  AST ≤ 5 x ULN

               -  ALT ≤ 5 x ULN

               -  Creatinine ≤ 3 x ULN

               -  Pulse Oximetry of >90% on room air

          4. Subject must have available autologous transduced activated T cells product at a dose
             of 2x10^8 cells/m^2 and meets the Certificate of Analysis acceptance criteria.

          5. No major surgery within 28 days prior to lymphodepletion.

          6. Negative serum pregnancy test within 72 hours prior to lymphodepleting therapy for
             female participants of childbearing potential. Note: Females are considered of
             childbearing potential unless they are surgically sterile (have undergone a
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
             naturally postmenopausal for at least 12 consecutive months.

          7. Subject has not received any investigational agents or any tumor vaccines within the
             previous six weeks prior to lymphodepletion.

          8. Subject has not received anti-CD30 antibody-based therapy within the previous 4 weeks
             prior to lymphodepletion.

          9. Subject has not received chemotherapy within the previous 3 weeks prior to
             lymphodepletion.

         10. Subject does not have rapidly progressive disease, per treating oncologist's
             discretion.

         11. Subject is a good candidate for CAR T cell therapy, per treating oncologist's
             discretion.

         12. Subjects on strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) as these
             may increase plasma concentrations of bendamustine, and decrease plasma concentrations
             of its metabolites. See http://medicine.iupui.edu/clinpharm/ddis/ for an updated list
             of strong inhibitors of CYP1A2. (This applies to subjects who receive bendamustine for
             lymphodepletion (required) up through 72 hours after the last dose of bendamustine.)

         13. Subject is not taking a prohibited or contraindicated medication prior to
             lymphodepletion.

         14. Current use of systemic corticosteroids at doses ≥10 mg prednisone daily or its
             equivalent; those receiving <10 mg daily may be enrolled at discretion of
             investigator. Inhaled steroids are allowed.

        Eligibility Criteria Prior to Cell Product Administration #1

          1. Subject has no evidence of uncontrolled infection or sepsis.

          2. Negative serum pregnancy within 7 days of cell product administration for females of
             childbearing potential (does not need to be repeated if pre-lymphodepletion pregnancy
             test is within window). Note: Females are considered of childbearing potential unless
             they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation,
             or bilateral oopherectomy) or they are naturally postmenopausal for at least 12
             consecutive months.

          3. Evidence of adequate organ function as defined by:

               -  Total bilirubin ≤ 2 × ULN, unless attributed to Gilbert's syndrome

               -  AST ≤ 5 × ULN

               -  ALT ≤ 5 × ULN

               -  Creatinine ≤ 3 × ULN

               -  Pulse Oximetry of >90% on room air

          4. Subject has no clinical indication of rapidly progressing disease in the opinion of
             the clinical investigator.

          5. Subject is a good candidate for treatment with ATLCAR.CD30 cell product per the
             clinical investigator's discretion.

        Eligibility Criteria Prior to Lymphodepletion #2

          1. Imaging results from within 21 days prior to lymphodepletion to confirm that the
             subject has derived clinical benefit from the initial infusion as assessed by the
             investigator (stable disease or better after the first ATLCAR.CD30 infusion without
             subsequent progressive disease).

          2. Subjects who experienced Grade 4 CRS or Grade 4 ICANS as a result of the initial
             ATLCAR.CD30 infusion are only eligible for a second round of lymphodepletion and
             infusion if they have partial response or better to the initial ATLCAR.CD30 infusion.

          3. Subject must demonstrate adequate organ function prior to lymphodepletion as defined
             below. All tests must be obtained within 24 hours prior to lymphodepletion:

               -  Absolute neutrophil count ≥ 1.0 × 10^9/L

               -  Platelet count ≥ 50 × 10^9/L

               -  Total bilirubin ≤ 2 × ULN, unless attributed to Gilbert's syndrome

               -  AST ≤ 5 × ULN

               -  ALT ≤ 5 × ULN

               -  Creatinine ≤ 3 × ULN

               -  Pulse Oximetry of >90% on room air

          4. Subject must have available autologous transduced activated T cells product at a dose
             of 2x10^8 cells/m^2 and meets the Certificate of Analysis acceptance criteria.

          5. Negative serum pregnancy test within 72 hours prior to lymphodepleting therapy for
             female participants of childbearing potential. Note: Females are considered of
             childbearing potential unless they are surgically sterile (have undergone a
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
             naturally postmenopausal for at least 12 consecutive months.

          6. Subject does not have evidence of uncontrolled infection or sepsis.

          7. Subject is not receiving a prohibited medication at time of starting lymphodepletion
             up through 72 hours after the last dose of cyclophosphamide.

          8. Subject is a good candidate for CAR T cell therapy, per treating oncologist's
             discretion.

          9. Current use of systemic corticosteroids at doses ≥10 mg prednisone daily or its
             equivalent; those receiving <10 mg daily may be enrolled at discretion of
             investigator. Inhaled steroids are allowed.

        Eligibility Criteria Prior to Cell Product Administration #2

          1. Subject has no evidence of uncontrolled infection or sepsis.

          2. Negative serum pregnancy within 7 days of cell product administration for females of
             childbearing potential (does not need to be repeated if pre-lymphodepletion pregnancy
             test is within window). Note: Females are considered of childbearing potential unless
             they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation,
             or bilateral oophorectomy) or they are naturally postmenopausal for at least 12
             consecutive months.

          3. Evidence of adequate organ function as defined by:

               -  Total bilirubin ≤ 2 × ULN, unless attributed to Gilbert's syndrome

               -  AST ≤ 5 × ULN

               -  ALT ≤ 5 × ULN

               -  Creatinine ≤ 3 × ULN

               -  Pulse Oximetry of >90% on room air

          4. Subject has no clinical indication of rapidly progressing disease in the opinion of
             the clinical investigator.

          5. Subject is a good candidate for treatment with ATLCAR.CD30 cell product per the
             clinical investigator's discretion.